Cystic fibrosis, the poster child grows up

In 1989, the median age at death for a person with cystic fibrosis in the United States was 28. In 2024, the median predicted age of survival for an infant born with cystic fibrosis in a country with access to modulator therapy is over 60. The disease has not changed. The molecular biology is the same misfolded chloride channel. The people who carry the variants are the same people. The thing that changed is the drugs, and the thing that built the drugs is a foundation model that other rare disease communities have copied and that pharmaceutical strategists now study by name.

What cystic fibrosis is

Cystic fibrosis is an autosomal recessive disorder caused by pathogenic variants in CFTR, the gene encoding the cystic fibrosis transmembrane conductance regulator. CFTR sits on the apical membrane of epithelial cells and pumps chloride out of the cell. When CFTR is absent or nonfunctional, salt and water transport across epithelial surfaces is disrupted. The clinical consequences appear wherever epithelial fluid balance matters: the airways, the pancreatic ducts, the intestinal lumen, the sweat glands, the male reproductive tract, the biliary tree.

The lung disease is the proximate cause of death in untreated and undertreated CF. Mucus on the airway surface becomes thick and dehydrated. Mucociliary clearance fails. Bacteria, particularly Pseudomonas aeruginosa, colonize the airways and produce a chronic inflammatory response. Bronchiectasis develops. Lung function declines over decades, and eventually respiratory failure or transplantation becomes necessary.

Pancreatic insufficiency develops in roughly eighty-five percent of people with classic CF and produces fat and protein malabsorption from infancy. Without enzyme replacement, growth fails. CF-related diabetes develops in many people with CF as the pancreatic insult progresses, typically in adolescence or adulthood. Liver involvement, intestinal complications including meconium ileus at birth and distal intestinal obstruction syndrome later, sinus disease, and male infertility from congenital absence of the vas deferens round out the multisystem picture.

CFTR has more than two thousand reported variants. The single most common pathogenic variant is F508del, a three-base-pair deletion that removes phenylalanine at position 508. F508del accounts for roughly seventy percent of CF alleles among people of Northern European ancestry. The variant produces a misfolded protein that is degraded before it reaches the cell surface. Other variants produce different molecular defects: stop codons, splice errors, gating defects, conductance defects. The molecular class of the variant determines which therapies are likely to help.

Reported live-birth incidence among people of Northern European ancestry runs roughly 1 in 2,500 to 1 in 3,500. Incidence is lower in East Asian and African populations. Detection in the United States is by newborn screening using immunoreactive trypsinogen, IRT, on the dried blood spot, with second-tier CFTR sequencing in elevated cases. All US states screen for CF. The condition is on the newborn screening panel of most high-income economies. Confirmation uses the sweat chloride test, which measures sweat electrolyte concentration after pilocarpine iontophoresis, plus CFTR sequencing.

What the foundation built

The Cystic Fibrosis Foundation was incorporated in 1955. For decades it functioned the way most disease nonprofits function: education, family support, awareness, modest research grants. In 1998 the foundation invested twenty-five million dollars in Aurora Biosciences, a small company developing high-throughput screening for compounds that might affect CFTR function. The model was unusual at the time. Disease nonprofits did not invest equity in commercial drug development. The foundation took the risk because the academic and pharmaceutical pipelines for CF were not producing therapies that addressed the underlying molecular defect.

Aurora was acquired by Vertex Pharmaceuticals in 2001. The CFTR modulator program continued. In 2012, Vertex received FDA approval for ivacaftor, marketed as Kalydeco, for people with the G551D gating-class variant. Approximately four percent of people with CF carried that variant. Ivacaftor was the first drug to address the underlying molecular defect of cystic fibrosis. It was also priced at roughly three hundred thousand dollars per patient per year. The financial proceeds returned to the foundation through the licensing agreement, which the foundation later sold for three and a quarter billion dollars in 2014.

The drug program continued. Lumacaftor plus ivacaftor, marketed as Orkambi, was approved in 2015 for F508del homozygotes. Tezacaftor plus ivacaftor, Symdeko, was approved in 2018. Elexacaftor plus tezacaftor plus ivacaftor, marketed as Trikafta in the United States and Kaftrio in Europe, was approved by the FDA in October 2019 for people aged 12 and older with at least one F508del variant, and the indication has expanded since then to include children as young as 2 with at least one F508del or one of dozens of other responsive variants. Trikafta is approved for roughly ninety percent of the CF population.

Trikafta produces effects that look like remission. FEV1 improves. Sweat chloride drops toward the disease-cutoff range. Sustained reductions in pulmonary exacerbations. Slowed decline of lung function over years. The benefit is not uniform across all responders, and Trikafta does not reverse established bronchiectasis or other structural damage, but the drug has changed the shape of the survival curve. Lung transplant referrals at major US CF centers have fallen. The CF Foundation Patient Registry shows median predicted age of survival now exceeding 60 years for an infant born today, compared with the late twenties in 1990.

Venture philanthropy as a template

The CF Foundation is the model commercial drug developers and other rare disease foundations point to when they describe venture philanthropy. The mechanics are now well documented: a disease foundation invests in clinical-stage development, takes equity or royalty rights in exchange, accelerates programs that conventional pharma capital would not back, and recycles proceeds into the next generation of programs. The model has been adopted by foundations focused on Type 1 diabetes, multiple myeloma, leukemia, and a growing list of rare diseases.

The replicability of the model has limits. Cystic fibrosis had biological characteristics that made it tractable: a single causative gene, a quantifiable biomarker (sweat chloride and CFTR functional measurements in cells), an identifiable population organized through accredited care centers, and a sufficient prevalence to support commercial pricing. Foundations attempting the same approach for genuinely ultra-rare diseases face an arithmetic problem. The pricing required to recoup development costs over a small population pushes per-patient costs into the millions, and the registry and care-center infrastructure that the CF Foundation built over decades does not exist for most conditions.

What CF still does not solve

Trikafta does not work for everyone with CF. Roughly ten percent of the CF population, including most people with two stop-codon or splice-site variants and some other classes of variants, do not respond to current modulators because the molecular defect is in the production of CFTR protein rather than in its folding or function. The unmet-need population is small in absolute numbers and concentrated in lower-income countries where access to modulator therapy is limited even for responders. Several mRNA-based and gene-replacement programs targeting the modulator-non-responder population are in clinical development.

Access to Trikafta also varies sharply by country. Pricing negotiations between Vertex and national health systems have produced uneven access across Europe and substantial barriers across most low and middle-income countries. The patent landscape and the cost structure of modulator therapy mean that the geographic disparity is likely to widen before it narrows.

The CF community has begun to grapple with what a near-normal lifespan looks like for people whose models of adulthood, family planning, and career trajectory were built around a 30-year life expectancy. Adult CF clinics that were small subspecialty programs in 1990 are now larger than the pediatric programs they grew out of. Pregnancy in women with CF, once unusual, is becoming common. Pulmonary transplant referrals are dropping. The disease that defined the field of pediatric pulmonology is now a chronic adult condition for the people who can access the drugs.